2 edition of Studies on immune responses to the HIV envelope glycoprotein gp120 found in the catalog.
Studies on immune responses to the HIV envelope glycoprotein gp120
Series of papers combined to form a thesis for the Department of Veterinary Microbiology, Section of Virology, Swedish University of Agricultural Sciences, Uppsala.
|The Physical Object|
|Pagination||various pagings :|
In addition to the virally encoded envelope glycoprotein gp/gp41, the HIV membrane also incorporates a plethora of cell membrane proteins in the process of assembly and budding. The HIV envelope proteins are expressed in the endoplasmic reticulum as a precursor protein, gp, which transits the Golgi apparatus, where glycosylation is. Human Immune Responses Toward HIV-1 Envelope Antigens (HIVBLD) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
HIV primarily infects CD4 + T cells via their receptor, CD4, along with chemokine receptors CXCR4 and CCR5 CD4 + T cells are critical in orchestrating cells of adaptive immunity, such as B cells and CD8 + T cells, HIV infection impairs the immune response against the virus itself. This phenomenon thus puts HIV at a unique advantage against the immune system. Abstract. The envelope glycoprotein gp of the human immunodeficiency virus (HIV), the causative agent of AIDS, contains approx 24 potential sites for N-glycosylation (Asn-X-Ser/Thr, X≠Pro) (), all of which are utilized and constitute about 50% of the molecular mass ().Binding of gp to the CD4 molecule is an initial step in viral infection of cells bearing the CD4 molecule on the Cited by: 3.
Since , a large panel of broad and potent monoclonal neutralizing antibodies (MoNAbs) against HIV-1 have been isolated. These MoNAbs can protect from lllV-1 infection and suppress established infection in animal models. Because their efficacy should be evaluated in human clinical trials, it is of importance to define the sensitivity of the most contemporary transmitted variants to these. Human immunodeficiency virus (HIV) 4 gains entry into permissive CD4 + cells by sequentially interacting with CD4, the primary receptor, and a co-receptor, usually either CCR5 or CXCR4 ().Both receptor and co-receptors are recognized by gp, the glycoprotein that constitutes the surface unit of HIV envelope spikes.
Journey to the Golden Pyramid
design of switching circuits
Thus spake Zarathustra
great American values test
Studies in Greek scenery, legend and history
Flowering trees and shrubs.
Beginning with ourselves in practice, theory, and human affairs
Review of Greenland activities 1998 / edited by A.K Higgins and W. Stuart Watt.
The history of churches in England
Cities against nature
A Wager for a Bride
A commentary to Sesame and Lilies of John Ruskin, LL.D., including biography, notes, and appendix
Antibody responses to the HIV-1 envelope glycoproteins can be classified into three groups. Binding but non-neutralizing responses are directed to epitopes that are expressed on isolated envelope glycoproteins but not on the native envelope trimer found on the surface of virions and responsible for mediating the entry of virus into target by: Philip M.
Murphy, in Clinical Immunology (Third Edition), Opposite effects of CCR5 in HIV and West Nile virus infection. HIV envelope glycoprotein gp mediates fusion of the viral envelope with the target cell membrane by binding to CD4 and a chemokine receptor.
30 Both CCR5 and CXCR4 physically associate with CD4 and gp, and are therefore referred to as ‘HIV co-receptors’. Envelope glycoprotein GP (or gp) is a glycoprotein exposed on the surface of the HIV was discovered by Professors Tun-Hou Lee and Myron "Max" Essex of the Harvard School of Public Health in The in its name comes from its molecular weight of is essential for virus entry into cells as it plays a vital role in attachment to specific cell surface ro: IPR Cynthia A.
Derdeyn, in Natural Hosts of SIV, Comparative Studies of HIV-1 and SIVsm/HIV-2 Antibody Responses. The envelope (env) gene of HIV/SIV is the most variable of viral genes and is the principal target of the humoral immune studies have focused on neutralizing antibody activity against Env in HIV/SIV infection, reflecting the reputed importance of this antibody.
For example, amphotropic murine leukemia virus (ampho-MLV) Env and vesicular stomatitis virus G glycoprotein (VSV-G) are frequently used to pseudotype HIV-1 particles.
Finally, a number of studies have shown that removal of most or virtually all of the gp41 CT has only a modest effect on Env glycoprotein incorporation into HIV-1 Cited by: The envelope glycoprotein (Env) of HIV performs the many complex steps needed for membrane fusion.
First, it attaches itself to proteins on the surface of the cell. Then, it acts like a spring-loaded mousetrap and snaps into a new conformation that drags the virus and cell close enough that the membranes fuse.
Involvement of Envelope-Glycoprotein Glycans in HIV-1 Biology and Infection Article Literature Review in Archivum Immunologiae et Therapiae Experimentalis 58(3) April with 18 Reads. Human immunodeficiency virus (HIV), a member of the retrovirus family, is the causative agent of acquired immunodeficiency syndrome (AIDS).HIV invades various immune cells (e.g., CD4+ T cells and monocytes) resulting in a decline in CD4+ T cell numbers below the critical level, and loss of cell-mediated immunity − therefore, the body becomes progressively more susceptible to opportunistic.
Structure-Based Stabilization of HIV-1 gp Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site Article (PDF Available) in PLoS Pathogens 5(5):e June with The glycoprotein gp41 is non-covalently bound to gp, and provides the second step by which HIV enters the cell.
It is originally buried within the viral envelope, but when gp binds to a CD4 receptor, gp changes its conformation causing gp41 to become exposed, where Entrez: Structure of an HIV gp envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
Nature ; Labrijn AF, Poignard P, Raja A, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp is sterically restricted on primary human immunodeficiency virus type 1.
In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp by antibodies to the CD4-binding site of gp Maria Luisa Visciano, Michael Tuen, Miroslaw K.
Gorny, Catarina E. Hioe⁎ Department of Pathology, New York University School of Medicine and VA New York Harbor Healthcare System – Manhattan Campus, New York, NYUSA. Several studies have described the development of vaccine strategies, including improved envelope proteins formulated with potent adjuvants, DNA and vectors expressing mosaics or conserved sequences, capable of inducing strong relevant immune responses, such as neutralizing antibodies (NAbs) and non-neutralizing antibodies, CD4 + and CD8 + cell Cited by: 1.
Humoral Immune Responses to HIV Infection, p In HIV and the Pathogenesis of AIDS, Third Edition. ASM Press, Washington, DC. doi: /ch The entry of human immunodeficiency virus (HIV) into cells requires the sequential interaction of the viral exterior envelope glycoprotein, gp, with the CD4 glycoprotein and a chemokine Cited by: Human immunodeficiency virus (HIV) AIDS is caused by the human immunodeficiency virus (HIV), a retrovirus of the lentivirus family that was unknown until the early 's, but since that time has been spread around the world to infect millions of persons.
including the outer envelope glycoprotein gp and transmembrane glycoprotein gp HIV uses various forms of molecular trickery to evade immune responses. Most antibodies capable of neutralizing HIV infection access only the surfaces involved in CD4 or CCR5 binding. Most of the envelope protein gp surface is hidden from circulating antibodies by glycosylation or by steric exclusion as gp (and gp41) form trimers (Wyatt.
Helseth, U. Olshevsky, C. Furman, and J. Sodroski, Human immunodeficiency virus type 1 gp envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein, J.
Virol. 65, – (). PubMed Google ScholarAuthor: Isidro Hötzel, William P. Cheevers. Development of new immunogens eliciting broadly neutralizing antibodies (bNAbs) is a main priority for the HIV-1 vaccine field. Envelope glycoproteins from non-B-non-C HIV-1clades have not been fully explored as components of a vaccine.
We produced Vaccinia viruses expressing a truncated version of gp (gpt) from HIV-1 clades CRF02_AG, H, J, B, and C and examined their immunogenicity in.
The HIV-1 envelope glycoprotein spike is the target of neutralizing antibody attack, and hence represents the only relevant viral antigen for antibody-based vaccine design. Various approaches have been attempted to recapitulate Env in membrane-anchored and soluble forms, and these will be discussed here in the context of recent successes and challenges still to be by:.
The HIV-1 envelope glycoprotein consists of the surface moiety gp, which is bound to the transmembrane protein gp The primary structure of gp can be subdivided into 5 relatively conserved regions and 5 variable loops (C1-V1-V2-C2-V3-C3 Cited by: Abstract Antibodies to the carboxy-terminal constant (C5) region 5 of the HIV-1 envelope glycoprotein gp have previously been associated with slow disease progression.
This is one of the regions on gp that interact with the transmembrane glycoprotein, gp41, anchoring it to the viral and infected cell membrane. This study analyzed humoral responses to a novel heterodimeric peptide Cited by: 3.One of the mechanisms by which HIV-1 evades antibody-mediated neutralizing responses is the remarkable conformational flexibility of its envelope glycoprotein (Env) gp Some recombinant gps do not preserve their conformations on gps and functional viral spikes, and exhibit decreased recognition by CD4 and neutralizing antibodies.